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I
n some ways, it is difﬁcult to imagine that more than
a quarter century has passed since the earliest
attempts to reverse type 1 diabetes through immune
modulation saw their genesis (1). Sadly, despite the
performance of a multitude of clinical trials during this
time period ranging from single case studies to large
multicenter collaborative efforts, no agent or methodology
has been identiﬁed as a proven means for reversing this
disorder in a setting meaningful to public health care de-
livery (2). These efforts, like those seeking to prevent the
disorder before its symptomatic onset, have not been de-
void of providing scientiﬁc beneﬁt as many intellectual
gains have been realized through their performance (3,4).
This would include improvements in assays for immuno-
logic and metabolic biomarkers of disease (e.g., autoanti-
bodies, C-peptide), standardization of tests for metabolic
function, the organization of large collaborative networks
(e.g., National Institutes of Health [NIH] TrialNet and Im-
mune Tolerance Network), as well as an improved un-
derstanding of the natural history for type 1 diabetes; many
facets of which have been reported over the years within
the pages of Diabetes.
To be clear, clinical trials seeking the reversal of type 1
diabetes are tough to perform for reasons large in number
and diverse in nature. Often, a therapeutic agent can be
difﬁcult to obtain from a pharmaceutical entity (especially
if it is in the early stages of development), and even when
available, it can be cost prohibitive. Beyond this, costs for
laboratory testing, patient care, travel, and mechanistic
studies contribute substantially to the bottom line of any
clinical trial. Organizational challenges include obtaining
regulatory approval at a local (i.e., institutional review
board) or national (e.g., U.S. Food and Drug Administra-
tion [FDA], European Medicines Agency) level, meeting
privacy and compliance issues, recruiting and retaining
trial staff, and more. However, once organized, among
the most difﬁcult facets—a n di ns o m et r i a l s ,the most
challenging—is that of patient recruitment. This is certainly
the case for clinical trials seeking to reverse type 1 diabetes.
Indeed, for many type 1 diabetic patients and their fami-
lies, the diagnosis of this disorder can carry with it a state
of emotional shock that for far too many, handicaps the
ability to make clear and wise decisions with conﬁdence.
While patients or their family members clearly desire to
select a clinical trial offering the best chance for thera-
peutic beneﬁt, another major factor inﬂuencing trial par-
ticipation involves questions related to the probability of
assignment to a control group, usually involving intensive
diabetes management alongside of additional clinic visits
for studies of disease mechanisms.
Double-blind, placebo-controlled trials have been the
mainstay, albeit not the exclusive model, for most clinical
trials seeking type 1 diabetes reversal, as they are for
a variety of clinical disorders. Without question, this gold
standard trial model provides the clearest medical in-
sights as it affords a means for comparing therapeutic
efﬁcacy among various study arms within an organized
system. Put bluntly, many view uncontrolled trials as
providing no benchmark for which to make key posttrial
decisions.
However, thanks to the recent efforts of some very well
conducted clinical trials at or near the onset of type 1 di-
abetes and, more importantly, some moderately successful
therapeutic outcomes in a few of these trials, we do now
have reasonably consistent data on the natural history of
the decline in b-cell function, an almost standard use of
C-peptide following a mixed-meal stimulation as an out-
come marker for b-cell reserve, and some idea of what
a successful treatment may look like as soon as 6 months
into a trial. It is for these reasons—knowledge gained from
past clinical trials, a desire to improve patient recruitment,
the need to be more efﬁcient with costs, and more—that
it may be time to consider changing the rules and opening
for debate two concepts for future clinical trials seeking
to reverse type 1 diabetes. Those concepts would be to
either develop a universal control group or move toward
a system of adaptive trial design (5–7), where a placebo-
control group could be “shared” as decisions regarding
trial design (including the addition of new agents, assessing
biomarkers as outcomes measures, etc.) are subjected to
change over time. The development and subsequent adop-
tion of either form of a control group in studies of type 1
diabetes reversal could provide at least ﬁve beneﬁts to both
health care providers and those with the disease.
First, when obtaining patient consent, knowledge that
randomization to a placebo arm is possible provides a de-
terrent to recruitment. Reducing the chances for assign-
ment to a group that is devoid of experimental treatment
should result in improvements with respect to subject
enrollment. Second, as noted previously, clinical research
is expensive to perform. While certainly variable and de-
pendent on the speciﬁc design of a given trial, it is con-
ceivable that substantial reduction in costs would occur
were this proposal adopted. From here, one could also
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gains that would occur with the system utilizing either
a universal control group or a program of adaptive design.
To the former, the beneﬁts of having a universal control
group of, for example, 600 patients versus a traditional
placebo control arm (in phase II a/b studies of type 1 di-
abetes reversal) of approximately 6 to 60 patients would
appear obvious. It is also plausible that pharmaceutical
companies and other funding agencies (both public and
private) would see this as a plus given the aforementioned
potential for cost reductions and allowances for compari-
son of agents against what would be a consistent standard.
Indeed, for years, the cost-beneﬁt ratio of performing
a clinical trial for type 1 diabetes reversal has not been in
industry’s favor relative to a therapeutic intervention for
type 2 diabetes or many other autoimmune disorders. In
addition, researchers have, to some extent, been handi-
capped in interpreting therapeutic efﬁcacy by publication
of clinical trial results lacking a standard reporting for-
mat (e.g., different ascertainment times, methods for
reporting C-peptide data). The adoption of trial designs
that redeﬁne control groups with standards amenable to
analysis of arms involving a variety of agents could help
change this.
There are several organizations and research con-
sortiums to thank for these advances. The NIH- and Ju-
venile Diabetes Research Foundation–supported TrialNet
Consortium put into place some standardized measure-
ments of b-cell function such as C-peptide quantiﬁcation
following the mixed-meal tolerance test. While there may
be more informative measures (e.g., the hyperglycemic
clamp), the mixed-meal tolerance test has proven itself as
both practical and informative by providing consistent
observations in the hands of different clinical sites and
trials. Industry has also helped by working with private
practitioners (i.e., investigators outside of traditional aca-
demia) in order to improve the number of available study
subjects as well. The impact of industry could, in theory,
be enhanced even more were raw data from trials more
readily available to the medical community.
Why are these past observations so important? If we
look at four major trials that have claimed efﬁcacy (8–11),
all showed a beneﬁt in the ﬁrst three months of follow-up
with an increase in C-peptide as compared with start of
treatment. For those efﬁcacious trials, as well as similar
trials failing to show efﬁcacy (12–15), a very consistent
slope of b-cell decline was observed in the control patients
as measured by area under the curve or peak C-peptide
following a mixed-meal challenge. The ﬁrst 12–18 months
show a linear drop in the control groups that approximates
30–40% of starting b-cell function per 12-month period.
Importantly, it is linear from time point zero. Although
there was an eventual decline in C-peptide in the efﬁca-
cious trials, a closer examination of the data suggests that
without stabilization of C-peptide concentrations in the
ﬁrst 3 months, there is little likelihood of efﬁcacy at 12
months or longer.
This is good news for all with agents subject to thera-
peutic testing for type 1 diabetes reversal. It is now con-
ceivable that small phase II trials with short follow-up
periods could be an effective way to test whether it is
worth pursuing an agent in type 1 diabetes. For example,
single treatment arm studies with a mere 3–6 months of
follow-up and mixed-meal challenges could provide sufﬁ-
cient information to render the decision to invest in further
testing of an agent and expansion to larger trials. What is
the basis for this notion? The mean C-peptide loss at 3
months in adolescents and adults in 2 trials, 1,25(OH)2
vitamin D3 and the anti-tumor necrosis factor drug Enbrel
(14,15), approximates 7%. With an SD of 10%, less than 20
patients in a treatment arm would be required to detect no
loss of C-peptide with 80% power, and 10 patients to detect
a rise of the magnitude seen in, for example, the NIH
TrialNet Anti-CD20 (Rituxan) trial (11). It is important to
note that this model would only be applicable to the pool
of patients with the characteristics of those used in recent
trials of similar entry characteristics and entry criteria (i.e.,
onset within 3 months, age range 12–35 years, a minimal
amount of residual C-peptide, and type 1 diabetes auto-
antibody positivity). With respect to children, we are still
waiting for reference points. However, these data could
soon become available because of the performance of
clinical trials in large numbers of children such as the
phase III Diamyd vaccine trial.
This is not to say that movement to control groups of
a different design than most current efforts would be
without their potential limitations. These models of trial
design have been criticized for their potential to increase
the risk for false assumptions because of type 1 or type 2
errors. Beyond statistical concerns, seemingly subtle dif-
ferences in diabetes management between investigators
performing a novel clinical trial and those practiced in the
universal or adaptive control group could be of inﬂuence
and result in false assumptions. Beyond this, for studies
where prospective mechanistic efforts are being performed
(e.g., T-cell assays or other immune markers), the limi-
tations afforded by a reduction in the number of placebo
control subjects could represent an impediment. Here, one
would hope that efforts under current consideration (e.g.,
the T1DExchange, NIH TrialNet Natural History Study)
seeking to obtain patient samples from individuals through-
out their natural history of type 1 diabetes may, in part, ﬁll
this void. In addition, standardso fc a r ef o rt y p e1d i a b e t e s
may change with time due to the implementation of new
therapeutic advances (e.g., continuous glucose monitoring,
insulin analogs, insulin pumps). Hence, with time, while the
adaptive trial design model may keep up with such changes,
a universal control group may need redeﬁning. This would
appear especially important for regulatory agencies such as
the FDA, where placebo-controlled phase III trials appear, as
noted above, as a gold standard.
It is also vital to note that before implementation of any
such effort, control arms from a series of clinical trials
having largely similar measurements (e.g., those of NIH
TrialNet) should be compared by statisticians and experts
in trial design to provide assurance that variances across
a series of study populations are not of a degree that would
render the proposed universal control or adaptive trial
design models unsound. Beyond this, thinking optimisti-
cally, should one of the agents currently in phase III
studies (e.g., Otelixizumab, Diamyd) receive FDA approval
as a standard therapy to extend endogenous b-cell func-
tion, then the nature of clinical trials in this area may
eventually, but not immediately, change. Speciﬁcally, for
ethical reasons, all studies moving forward may require
providing a standard of care arm with one of the approved
therapies that is compared with the novel therapy to be
evaluated, and thus a true placebo group may not be
readily available.
Lastly, from an ethical perspective, one could question
the value of continually assigning individuals having type 1
diabetes to the placebo-based arm of trial after trial for
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beyond that which may be associated with more active
care involved in research study participation. Indeed, this
latter notion has recently been called into question in
a variety of disorders where the clinical sequela and po-
tential for mortality are high or the outcomes of conven-
tional treatment are largely predictable (16).
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